Caspian Therapeutics, Inc.
PrivateLast Round
Series B
Sep 8, 2026
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Caspian Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in San Diego, California. It was founded in 2026.
Caspian Therapeutics, Inc. is a biotechnology company developing small-molecule menin inhibitors as disease-modifying therapies for diabetes and cardiometabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Caspian Therapeutics, Inc. Comparables
Compare Caspian Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biomea Fusion | 85% | |
| DiogenX | 82% | |
| Betavive Ltd. | 78% |
For institutional investors. Book with your work email.
Caspian Therapeutics, Inc. Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Caspian Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Suvretta Capital Management | Series B |
| BVF Partners L.P. | Series B |
| JDRF | Series B |
| Invus | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 8, 2026
$50M round led by BVF Partners L.P.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 4, 2026
Caspian Therapeutics, Inc. is developing KO-7246 to regenerate patients' own pancreatic beta cells and plans to test it in healthy volunteers in 2027 and diabetes patients in 2028.
- receives_financingOct 13, 2026
On Oct 1st '26, Caspian Therapeutics, Inc. launched with $50M in financing, led by BVF Partners with participation from T1D Fund, Invus, Montanova, Eli Lilly, Kura Oncology, Kura’s leadership team and biotech entrepreneurs, to advance KO-7246 through IND-enabling studies and into Phase 1 clinical development in California.
- is_developingOct 13, 2026
Caspian Therapeutics, Inc. launches a diabetes venture with Kura Oncology to develop KO-7246, an oral menin inhibitor, with $50 million in financing and plans IND-enabling studies before healthy-volunteer trials in 2027.
For institutional investors. Book with your work email.
Caspian Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Caspian Therapeutics, Inc.'s valuation, stock price, and market status.
Is Caspian Therapeutics, Inc. a public or private company?
Caspian Therapeutics, Inc. is a private company.
What is the current stock price of Caspian Therapeutics, Inc.?
Caspian Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Caspian Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Caspian Therapeutics, Inc. worth (valuation)?
Valuation information for Caspian Therapeutics, Inc. is not publicly available.
Can I buy Caspian Therapeutics, Inc. stock?
Caspian Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Caspian Therapeutics, Inc.'s last funding round?
Caspian Therapeutics, Inc.'s most recent funding round was Series B on September 8, 2026.
Who are the main investors in Caspian Therapeutics, Inc.?
Key investors in Caspian Therapeutics, Inc. include BVF Partners L.P..
Will Caspian Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Caspian Therapeutics, Inc..
How can I track Caspian Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Caspian Therapeutics, Inc.'s shares on secondary markets.